Key points from article :
NETSseq technology profiles specific brain cell types using post mortem human brain tissue samples from donors.
Cerevance collected over 7,000 human brain tissue samples from donors ranging in age from 8 to 97.
Scientists use antibodies against nuclear proteins, endoplasmic reticulum proteins, and membrane proteins.
With NETSseq technology scientists can also compare healthy and diseased cells, subpopulations.
Company is now working on a specific compound for the treatment of Parkinson’s disease called CVN424.
Company is raising $60m for the CVN424 program and for starting at least 4 new programs.
